The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-Associated phospholipase A2 for evaluation in man
- 16 September 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (18) , 2603-2606
- https://doi.org/10.1016/s0960-894x(02)00473-0
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidonesBioorganic & Medicinal Chemistry Letters, 2002
- Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetCurrent Opinion in Pharmacology, 2001
- N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2Bioorganic & Medicinal Chemistry Letters, 2000
- Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart DiseaseNew England Journal of Medicine, 2000
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitorBiochemical Journal, 1999
- Characterization of Isoleucyl-tRNA Synthetase from Staphylococcus aureusJournal of Biological Chemistry, 1998
- Purification, Properties, Sequencing, and Cloning of a Lipoprotein-Associated, Serine-Dependent Phospholipase Involved in the Oxidative Modification of Low-Density LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 1996